Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 29, 2022
Share
Registered Plan Private Investments Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was CAD 0.053522 million compared to CAD 0.036167 million a year ago.
Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a personâs vascular endothelium - the vital innermost lining of a personâs cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a personâs cardiovascular health.